CN1344268A - 咪唑[1,5－a]吡啶并[3,2－e]吡嗪酮作为药物的应用 - Google Patents

咪唑[1,5－a]吡啶并[3,2－e]吡嗪酮作为药物的应用 Download PDF

Info

Publication number
CN1344268A
CN1344268A CN00805307A CN00805307A CN1344268A CN 1344268 A CN1344268 A CN 1344268A CN 00805307 A CN00805307 A CN 00805307A CN 00805307 A CN00805307 A CN 00805307A CN 1344268 A CN1344268 A CN 1344268A
Authority
CN
China
Prior art keywords
alkyl
formula
compound
aryl
pyrido
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN00805307A
Other languages
English (en)
Chinese (zh)
Inventor
N·赫夫根
S·斯泽伦伊
M·德根哈德
U·埃格尔兰德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AWD Pharma GmbH and Co KG
Original Assignee
Arzneimittelwerk Dresden GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE1999102082 external-priority patent/DE19902082A1/de
Priority claimed from DE1999161302 external-priority patent/DE19961302A1/de
Application filed by Arzneimittelwerk Dresden GmbH filed Critical Arzneimittelwerk Dresden GmbH
Publication of CN1344268A publication Critical patent/CN1344268A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CN00805307A 1999-01-20 2000-01-14 咪唑[1,5－a]吡啶并[3,2－e]吡嗪酮作为药物的应用 Pending CN1344268A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DE1999102082 DE19902082A1 (de) 1999-01-20 1999-01-20 Verwendung von Imidazo[1,5-a]-pyrido[3,2-e]-pyrazinonen als Inhibitoren der Phosphodiesterase 5 zur Therapie von erectiler Dysfunktion und Verfahren zu deren Herstellung
DE19902082.5 1999-01-20
DE19961302.8 1999-12-18
DE1999161302 DE19961302A1 (de) 1999-12-18 1999-12-18 Verwendung von Imidazo(1,5-a)-pyrido(3,2-e)-pyrazinonen als duale Inhibitoren der Phosphodiesterase 5 und der Phosphodiesterase 3 zur Therapie der Herzinsuffizienz, von pulmonaler Hypertonie und Gefäßerkrankungen, die mit einer Minderdurchblutung einhergehen

Publications (1)

Publication Number Publication Date
CN1344268A true CN1344268A (zh) 2002-04-10

Family

ID=26051406

Family Applications (1)

Application Number Title Priority Date Filing Date
CN00805307A Pending CN1344268A (zh) 1999-01-20 2000-01-14 咪唑[1,5－a]吡啶并[3,2－e]吡嗪酮作为药物的应用

Country Status (23)

Country Link
EP (1) EP1144410A2 (ko)
JP (1) JP2002535330A (ko)
KR (1) KR20010101603A (ko)
CN (1) CN1344268A (ko)
AR (1) AR022318A1 (ko)
AU (1) AU2291200A (ko)
BG (1) BG105714A (ko)
BR (1) BR0007613A (ko)
CA (1) CA2296224A1 (ko)
CO (1) CO5190700A1 (ko)
CZ (1) CZ20012627A3 (ko)
EA (1) EA200100792A1 (ko)
EE (1) EE200100377A (ko)
HU (1) HUP0105132A3 (ko)
ID (1) ID29790A (ko)
IL (1) IL144156A0 (ko)
IS (1) IS5987A (ko)
LT (1) LT2001078A (ko)
LV (1) LV12793B (ko)
NO (1) NO20013334L (ko)
SK (1) SK10322001A3 (ko)
TR (1) TR200102121T2 (ko)
WO (1) WO2000043392A2 (ko)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101553491B (zh) * 2006-12-13 2013-05-29 Aska制药株式会社 喹喔啉衍生物
CN104703987A (zh) * 2011-10-10 2015-06-10 H.隆德贝克有限公司 具有咪唑并吡嗪酮骨架的pde9抑制剂
US9434733B2 (en) 2012-01-26 2016-09-06 H. Lundbeck A/S PDE9 inhibitors with imidazo triazinone backbone
US10513524B2 (en) 2015-07-07 2019-12-24 H. Lundbeck A/S PDE9 inhibitors with imidazo triazinone backbone and imidazo pyrazinone backbone for treatment of peripheral diseases
US12006319B2 (en) 2018-05-25 2024-06-11 Cardurion Pharmaceuticals, Inc. Monohydrate and crystalline forms of 6-[(3S,4S)-4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-3-tetrahydropyran-4-yl-7H-imidazo[1,5-a]pyrazin-8-one

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6548490B1 (en) * 1997-10-28 2003-04-15 Vivus, Inc. Transmucosal administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction
US6403597B1 (en) 1997-10-28 2002-06-11 Vivus, Inc. Administration of phosphodiesterase inhibitors for the treatment of premature ejaculation
WO2003051346A2 (en) * 2001-12-17 2003-06-26 Altana Pharma Ag Use of selective pde5 inhibitors for treating partial and global respiratory failure
FR2835741B1 (fr) * 2002-02-12 2006-05-05 Oreal Nouveaux coupleurs 6-alcoxy-2,3-diaminopyridine utiles pour la teinture des fibres keratiniques
US6916345B2 (en) 2002-02-12 2005-07-12 L'oreal S.A. 6-alkoxy-2,3-diaminopyridine couplers for dyeing keratin fibres
DE10325813B4 (de) 2003-06-06 2007-12-20 Universitätsklinikum Freiburg Prophylaxe und/oder Therapie bei der portalen Hypertonie
AU2005277384B2 (en) * 2004-08-17 2011-11-17 The Johns Hopkins University PDE5 inhibitor compositions and methods for treating cardiac indications
US20090143361A1 (en) * 2007-11-30 2009-06-04 Elbion Gmbh Pyrido[3,2-E]Pyrazines, Process For Preparing The Same, And Their Use As Inhibitors Of Phosphodiesterase 10
AU2008329775A1 (en) 2007-11-30 2009-06-04 Biotie Therapies Gmbh Aryl and heteroaryl fused imidazo[1,5-a]pyrazines as inhibitors of phosphodiesterase 10
JP5842640B2 (ja) * 2012-01-31 2016-01-13 株式会社東洋新薬 ホスホジエステラーゼ３阻害剤
US9938284B2 (en) 2014-08-07 2018-04-10 Intra-Cellular Therapies, Inc. Organic compounds
US10005789B2 (en) 2014-08-07 2018-06-26 Intra-Cellular Therapies, Inc. Organic compounds

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5055465A (en) * 1989-05-31 1991-10-08 Berlex Laboratories, Inc. Imidazoquinoxalinones, their aza analogs and process for their preparation
DE19510965A1 (de) * 1995-03-24 1996-09-26 Asta Medica Ag Neue Pyrido/3,2-e/pyrazinone mit antiasthmatischer Wirksamkeit und Verfahren zu deren Herstellung

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101553491B (zh) * 2006-12-13 2013-05-29 Aska制药株式会社 喹喔啉衍生物
CN104703987A (zh) * 2011-10-10 2015-06-10 H.隆德贝克有限公司 具有咪唑并吡嗪酮骨架的pde9抑制剂
CN104703987B (zh) * 2011-10-10 2017-05-03 H.隆德贝克有限公司 具有咪唑并吡嗪酮骨架的pde9抑制剂
US9643970B2 (en) 2011-10-10 2017-05-09 H. Lundbeck A/S Substituted imidazo [1,5-a]pyrazines as PDE9 inhibitors
US9993477B2 (en) 2011-10-10 2018-06-12 H. Lundbeck A/S Substituted imidazo[1,5-a]pyrazines as PDE9 inhibitors
US9434733B2 (en) 2012-01-26 2016-09-06 H. Lundbeck A/S PDE9 inhibitors with imidazo triazinone backbone
US9533992B2 (en) 2012-01-26 2017-01-03 H. Lundbeck A/S PDE9 inhibitors with imidazo triazinone backbone
US9850249B2 (en) 2012-01-26 2017-12-26 H. Lundbeck A/S PDE9 inhibitors with imidazo triazinone backbone
US10513524B2 (en) 2015-07-07 2019-12-24 H. Lundbeck A/S PDE9 inhibitors with imidazo triazinone backbone and imidazo pyrazinone backbone for treatment of peripheral diseases
US11608342B2 (en) 2015-07-07 2023-03-21 H. Lundbeck A/S PDE9 inhibitors with imidazo triazinone backbone and imidazo pyrazinone backbone for treatment of peripheral diseases
US12006319B2 (en) 2018-05-25 2024-06-11 Cardurion Pharmaceuticals, Inc. Monohydrate and crystalline forms of 6-[(3S,4S)-4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-3-tetrahydropyran-4-yl-7H-imidazo[1,5-a]pyrazin-8-one

Also Published As

Publication number Publication date
CO5190700A1 (es) 2002-08-29
WO2000043392A2 (de) 2000-07-27
JP2002535330A (ja) 2002-10-22
IL144156A0 (en) 2002-05-23
IS5987A (is) 2001-06-29
KR20010101603A (ko) 2001-11-14
NO20013334D0 (no) 2001-07-05
AR022318A1 (es) 2002-09-04
LT2001078A (en) 2002-08-26
NO20013334L (no) 2001-07-05
EE200100377A (et) 2002-10-15
SK10322001A3 (sk) 2002-07-02
CZ20012627A3 (cs) 2002-01-16
EP1144410A2 (de) 2001-10-17
ID29790A (id) 2001-10-11
HUP0105132A2 (hu) 2002-05-29
TR200102121T2 (tr) 2002-01-21
CA2296224A1 (en) 2000-07-20
AU2291200A (en) 2000-08-07
LV12793B (lv) 2002-05-20
LV12793A (lv) 2002-02-20
EA200100792A1 (ru) 2002-10-31
HUP0105132A3 (en) 2002-12-28
BG105714A (en) 2002-02-28
BR0007613A (pt) 2001-10-30
WO2000043392A3 (de) 2000-09-28

Similar Documents

Publication Publication Date Title
CN1344268A (zh) 咪唑[1,5－a]吡啶并[3,2－e]吡嗪酮作为药物的应用
CN1112928C (zh) Cgmp磷酸二酯酶抑制剂在制备治疗阳茎障碍的药物中的用途
US6143757A (en) Chemical compounds
JP3577630B2 (ja) 勃起不全治療に効果を持つピラゾロピリミジノン化合物
JP5618548B2 (ja) イミダゾ［１，２−ａ］ピリジンおよびそれらの薬剤としての使用
JP4220779B2 (ja) 化学化合物
US20040087599A1 (en) cGMP-PDE inhibitors for the treatment of erectile dysfunction
EP2327408A1 (en) Tetracyclic cyclic gmp-specific phosphodiesterase inhibitors for the treatment of benign prostatic hypertrophy
IL152873A (en) Beta-carboline derivatives for use as phosphodiesterase inhibitors
CN1607952A (zh) 包含多官能磷酸二酯酶抑制剂和腺苷吸收抑制剂的药物组合物
SK13232002A3 (sk) Použitie pyrido[3,2-e]-pyrazinónov ako inhibítorov fosfodiesterázy 5 na liečbu erektilnej dysfunkcie
US6800625B2 (en) Substituted 2,4-dihydro-pyrrolo[3,4-b]quinolin-9-one derivatives useful as phosphodiesterase inhibitors
JPH05155887A (ja) アゾール誘導体
CN103360398B (zh) 一种三唑并嘧啶类hiv-1逆转录酶抑制剂及其制备方法与应用
JP6633246B2 (ja) ヒトｐｄｅ１阻害薬として有用なトリアゾロピラジノン誘導体
JP2004536816A (ja) Ｐｄｅ５阻害剤としてのカルボリン誘導体
JP2008546712A (ja) ラクタム含有ｈｃｖ感染阻害剤
US20080171746A1 (en) Method for Preventing Cardiovascular Diseases
CN1095592A (zh) 血管紧张素ii拮抗剂的新用途
CN103073554A (zh) 一种取代吡咯色原酮类化合物
CN1111406C (zh) 含咪唑衍生物的抗hiv组合物
MXPA01007380A (en) Use of imidazo[1,5-a]-pyrido[3,2-e]-pyrazinones as medicaments
CN103083313A (zh) 一种取代吡咯色原酮类化合物在制备治疗5型磷酸二酯酶相关疾病的药物中的应用
CN1193029C (zh) 7－氨基吡啶并[2,3－d]嘧啶衍生物，其组合物及用途
JP2002255937A (ja) 新規化合物

Legal Events

Date Code Title Description
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C06 Publication
PB01 Publication
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication